Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of F01 (SNC103) in Relapsed/Refractory Non-Hodgkin Lymphoma
NCT06206902Phase 1Recruiting
- Sponsor
- Simnova Biotherapeutics
- Start
- Apr 2024
- Primary completion
- Jan 2025
- Modality
- CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SNC103 in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), sponsored by Simnova Biotherapeutics. Primary endpoint: Safety of F01 cells at 24 months. Started Apr 2024; status: recruiting.
02
Drugs
SNC103
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT06206902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06206902.